Exploring polypharmacy with artificial intelligence: data analysis protocol

[1] Schumock GT(2019)National trends in prescription drug expenditures and projections for 2019 Am J Health Syst Pharm 76 1105-1121

[2] Stubbings J(2016)The high cost of prescription drugs in the United States: origins and prospects for reform JAMA 316 858-871

[3] Hoffman JM(2020)Forecasting drug utilization and expenditure: ten years of experience in Stockholm BMC Health Serv Res 20 410-1021

[4] Wiest MD(2016)Factors contributing to increases in prescription drug expenditures borne by National Health Insurance in South Korea Yonsei Med J 57 1016-174

[5] Suda KJ(2013)The impact of increasing polypharmacy on prescribed drug expenditure-a register-based study in Sweden 2005–2009 Health Policy 109 166-187

[6] Rim MH(2020)An overview of prevalence, determinants and health outcomes of polypharmacy Ther Adv Drug Saf 11 2042098620933741-e108

[7] Kesselheim AS(2020)Adverse outcomes of polypharmacy in older people: systematic review of reviews J Am Med Dir Assoc 21 181-618

[8] Avorn J(2020)Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis Oncologist 25 e94-924

[9] Sarpatwari A(2015)Register-based indicators for potentially inappropriate medication in high-cost patients with excessive polypharmacy Pharmacoepidemiol Drug Saf 24 610-401

[10] Linnér L(2009)Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia Can Soc Sci Med 68 919-116

[1] Schumock GT(2019)National trends in prescription drug expenditures and projections for 2019 Am J Health Syst Pharm 76 1105-1121

[2] Stubbings J(2016)The high cost of prescription drugs in the United States: origins and prospects for reform JAMA 316 858-871

[3] Hoffman JM(2020)Forecasting drug utilization and expenditure: ten years of experience in Stockholm BMC Health Serv Res 20 410-1021

[4] Wiest MD(2016)Factors contributing to increases in prescription drug expenditures borne by National Health Insurance in South Korea Yonsei Med J 57 1016-174

[5] Suda KJ(2013)The impact of increasing polypharmacy on prescribed drug expenditure-a register-based study in Sweden 2005–2009 Health Policy 109 166-187

[6] Rim MH(2020)An overview of prevalence, determinants and health outcomes of polypharmacy Ther Adv Drug Saf 11 2042098620933741-e108

[7] Kesselheim AS(2020)Adverse outcomes of polypharmacy in older people: systematic review of reviews J Am Med Dir Assoc 21 181-618

[8] Avorn J(2020)Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis Oncologist 25 e94-924

[9] Sarpatwari A(2015)Register-based indicators for potentially inappropriate medication in high-cost patients with excessive polypharmacy Pharmacoepidemiol Drug Saf 24 610-401

[10] Linnér L(2009)Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia Can Soc Sci Med 68 919-116